Skip to main content

Companion Diagnostic Market is Growing Dynamically at a Trendy CAGR of 15.4% During Forecast to 2023


Market Scope:
Companion diagnostics (CDx) are assaysor medical devices which provides information on the safe consumption or use of a drug or biological product. The test can determine the compatibility of the drug with the patient. Personalized medicine has pushed such devices to the forefront with many patients opting for this safe service to nullify side-effects of any drugs. Market Research Future (MRFR) asserts in its latest companion diagnostic market report the various developments and trends which can take place during the period of 2018 to 2023 (forecast period).
The global Companion Diagnostic Market Growth is set to touch a valuation of USD 12,647.5 million by 2023. It is pegged to display a CAGR of 15.4% over the forecast period. High costs of drug discovery and drug development is the primary factor driving market growth. CDx devices can provide vital information on the safety of drugs with respect to the individual. The use of these devices by pharmaceutical companies for improving the clinical outcomes of new drugs can positively impact the market.
Improving the validity and accuracy of biomarkers for identifying cancerous cells can also fuel market growth. The adoption of personalized medicine and chances of improving patient outcomes that can lower healthcare costs and minimize drug use can have a positive impact on the global companion diagnostic market.
However, the concerns over inaccuracy of test results may impede the market growth.
Competition Outlook:
F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, ARUP Laboratories, Abbott Laboratories, and Myriad Genetics, Inc.
Segmentation:
·         The global companion diagnostics marketreport is segmented by technology, application, and end user.
·         By technology, it has been segmented into polymerase chain reaction (PCR), in-situ hybridization, and immunohistochemistry. In-situ hybridization is a method in which modified DNA or RNA strands are used to localize a particular group of DNA or RNA in a section of the tissue. It can reveal the location of specific chromosomes, which can be used to target specific group of cells without affecting the neighboring cells. Immunohistochemistry is an examination for identification of carcinomas of unknown primary site (CUP). It can be used in identification and classification of cancerous cells in the body.
·         Applications in the companion diagnostics market comprise as central nervous system disorders, cancer, infectious diseases, cardiovascular diseases, and others.  Cancer is a disease which is accountable for many deaths annually. Companion diagnostics falls under pharmacogenomics which uses the genetic makeup of an individual for creating drugs suited for that individual. The success of personalized medicine using CDx assays as a base for identification of such traits can bode well for the market. Neurological disorders have a genetic disposition and scientists are redoubling their efforts at creating effective biomarkers for treating disorders such as Alzheimer’s.
·         By end user, the companion diagnostics market caters to clinical laboratories, contract research organizations, pharma & biotech companies, and others.
Regional Analysis:
The global companion diagnostics market, based on region, is divided into the Americas, Europe, AsiaPacific (APAC), and the Middle East & Africa (MEA).
The Americas can continue to dominate the global companion diagnostics market. Within the region, North America can lead mainly due to an established healthcare system and technological advancement in drugs. Presence of large number of players has led to collaborations and partnerships between pharmaceutical companies and firms specializing in companion diagnostics.
Europe has assumed the second-largest position in the market. Focus on improving imaging and assays for chronic diseases as well as focus on targeted therapies for oncology can induce demand in the global companion diagnostic market. Germany and the U.K. are expected to be the biggest revenue generators of the region.
 NOTE : Our team of researchers are studying Covid19 and its impact on various industry         verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.


Labels:

Comments

Post a Comment

Popular posts from this blog

Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis and Forecast to 2023

Market Overview: The Global Respiratory Therapeutic Devices Market is predicted to scale to new heights and expand at a CAGR of 10.8% over the forecast period of 2017-2023, asserts Market Research Future (MRFR) in an in-depth study.                   The growth of the Global Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis   is primarily led by the recent surge in the incidence of chronic respiratory diseases such as asthma, COPD, and sleep disorder breathing. As per the estimates of the World Health Organization (WHO), approximately 235 Mn people suffered from asthma in 2017 across the globe. The growing burden of chronic respiratory diseases (CRDs) induces strong demand for respiratory therapeutic devices within the market. Moreover, with the increase in the global aging population, there is a greater need for respiratory therapeutic devices.     ...
Post a Comment
Read more

Antibody Drug Conjugate Market is Presumed to Grow at a Reliable CAGR of 19% During Forecast to 2023

Antibody Drug Conjugate Market Analysis: Various factors are adding to the global antibody drug conjugate market share. These factors, as per the new MRFR report, include advances in medical technology, rising cases of cancer, growing obese population, and increasing aging population. Additional factors adding market growth include increasing collaborations between biotechnology companies, biopharmaceuticals, and research institutes, rising R&D on oncology diseases, increasing research on advanced drug discoveries, rising number of research on antibody therapies, and preclinical research. The global Antibody Drug Conjugate Market Share is likely to grow at a 19% CAGR between 2017- 2023 , reveals the new Market Research Future (MRFR) report. Antibody drug conjugates are new-age therapeutic agents that have three parts- a chemical linker to attach cytotoxic agents to antibodies, cytotoxic agents for killing target cancer cells, and specific antibodies for binding. Lymphoma, mult...
Post a Comment
Read more

Desalting and Buffer Exchange Market is Growing at a Healthy CAGR of 10.5% During Forecast to 2023

Market Highlights: The Global Desalting and Buffer Exchange Market is anticipated to have held a market value of USD 615.20 million in the year 2017 and is expected to grow at a CAGR of 10.5% during the forecast period. Desalting and buffer exchange play a key role in biotechnological companies. Buffer exchange is used to place a protein solution into a more suitable buffer before applications such as electrophoresis, ion exchange, affinity chromatography among others. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6633 Buffer exchange is the term used when one set of buffer salts in a sample is exchanged by another more appropriate buffer set. The rising demand for monoclonal antibodies, growing research and development expenditure by the biopharmaceutical companies, and rising focus on proteomic and genomic research is anticipated to boost the growth of the market over the forecast period. However, the dearth of skilled professionals is excepted to ...
Post a Comment
Read more